1/2期AAV5-hRKp.RPGR(Botaretigene Sparoparvovec)基因治疗:RPGR相关X连锁视网膜色素变性的安全性与疗效
这项开放标签1/2期剂量递增/扩展研究评估了AAV5-hRKp.RPGR在RPGR相关X连锁视网膜色素变性男性患者中的安全性与疗效。治疗总体安全耐受,无剂量限制性事件,多数不良事件为短暂的手术相关事件;与延迟治疗对照组相比,第26周视网膜敏感度和功能性视力有改善,第52周观察到相似趋势。
要点
- AAV5-hRKp.RPGR在RPGR相关X连锁视网膜色素变性中安全且耐受良好,未报告剂量限制性事件。
- 多数不良事件为短暂的手术相关事件,无需干预即可缓解;所有眼部炎症相关不良事件对糖皮质激素有反应。
- 与延迟治疗组相比,第26周视网膜敏感度和功能性视力有改善,第52周观察到相似趋势。
核心结论
- AAV5-hRKp.RPGR在52周内表现出可预期且可管理的不良事件特征,安全性和疗效结果支持在3期试验中进一步研究。
研究设计与样本
- 开放标签、1/2期剂量递增/扩展研究(ClinicalTrials.gov标识符:NCT03252847),纳入≥5岁患有RPGR相关X连锁视网膜色素变性的男性。
- 剂量递增阶段:对视力较差眼行视网膜下注射AAV5-hRKp.RPGR(低剂量:1.0 × 10^11 vg/ml;中剂量:2.0 × 10^11 vg/ml;高剂量:4.0 × 10^11 vg/ml),共10例。
- 剂量确认(中剂量)在3例儿童参与者中进行。
- 剂量扩展阶段:36例参与者按1:1:1随机分配至立即治疗(低或中剂量)或延迟治疗(对照)。
- 立即治疗参与者评估52周安全性和疗效,对照参与者评估26周。
主要发现
- AAV5-hRKp.RPGR安全且耐受良好,未报告剂量限制性事件。
- 多数不良事件为短暂的手术相关事件,无需干预即可缓解。
- 立即治疗组报告2例严重不良事件(视网膜脱离、葡萄膜炎);第三例严重不良事件(眼压升高)在报告期外报告。
- 所有眼部炎症相关不良事件对糖皮质激素有反应。
- 与延迟治疗组相比,第26周AAV5-hRKp.RPGR治疗使视网膜敏感度和功能性视力有改善;第52周观察到相似趋势。
关键数值与推荐
- 主要结局为安全性。
- 次要疗效结局包括静态视野检查、微视野检查、视力引导移动性、最佳矫正视力和对比敏感度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the safety and efficacy of AAV5-hRKp.RPGR in participants with retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa (XLRP). DESIGN: Open-label, phase 1/2 dose escalation/expansion study (ClinicalTrials.gov Identifier: NCT03252847). METHODS: Males (≥5 years old) with XLRP-RPGR were evaluated. In the dose escalation phase, subretinal AAV5-hRKp.RPGR (low: 1.0 × 1011 vg/ml; intermediate: 2.0 × 1011 vg/ml; high: 4.0 × 1011 vg/ml) was administered to the poorer-seeing eye (n = 10). Dose confirmation (intermediate dose) was carried out in 3 pediatric participants. In the dose expansion phase, 36 participants were randomized 1:1:1 to immediate (low or intermediate dose) or deferred (control) treatment. The primary outcome was safety. Secondary efficacy outcomes included static perimetry, microperimetry, vision-guided mobility, best corrected visual acuity, and contrast sensitivity. Safety and efficacy outcomes were assessed for 52 weeks for immediate treatment participants and 26 weeks for control participants. RESULTS: AAV5-hRKp.RPGR was safe and well tolerated, with no reported dose-limiting events. Most adverse events (AEs) were transient and related to the surgical procedure, resolving without intervention. Two serious AEs were reported with immediate treatment (retinal detachment, uveitis). A third serious AE (increased intraocular pressure) was reported outside the reporting period. All ocular inflammation-related AEs responded to corticosteroids. Treatment with AAV5-hRKp.RPGR resulted in improvements in retinal sensitivity and functional vision compared with the deferred group at Week 26; similar trends were observed at Week 52. CONCLUSIONS: AAV5-hRKp.RPGR demonstrated an anticipated and manageable AE profile through 52 weeks. Safety and efficacy findings support investigation in a phase 3 trial.
引用
- Michaelides M, Besirli CG, Yang Y, et al. Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa. Am J Ophthalmol. 2024. PMID: 38871269. doi:10.1016/j.ajo.2024.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。